Germany's new cost-benefit system gets underway
21 December 2009
Francesca Bruce
Please Login to read the full article.
21 December 2009
Francesca Bruce
Antidepressants and the anti-thrombotic clopidogrel are to be the first drugs to undergo the new cost-benefit assessment method developed by Germany's health technology assessment body IQWiG. However, this new method has failed to impress the pharmaceutical industry.
The
G-BA,...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Will sequestration be a better outcome for biopharma?
- 7th Annual Scrip Awards: Novartis, Jimenez, Burrill, Glenmark, ICON win
- Brilique beats rival clopidogrel for ACS: now NICE would like Efient comparison
- US Capitol Capsule: And they're off: First Supreme Court health reform briefs filed
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
